Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biodesix, Inc. - Common Stock (NQ:BDSX)

0.2822 +0.0319 (+12.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biodesix, Inc. - Common Stock

< Previous 1 2 3 4 Next >
PierianDx and Biodesix Partner to Advance Lung Cancer Diagnostics
From PierianDx
Via Business Wire
Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results
From Biodesix, Inc.
Via Business Wire
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer
From Biodesix, Inc.
Via Business Wire
Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer
From Biodesix
Via Business Wire
Biodesix Announces Third Quarter 2021 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021
From Biodesix, Inc.
Via Business Wire
Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
From Biodesix, Inc.
Via Business Wire
Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Second Quarter 2021 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test
From Biodesix, Inc.
Via Business Wire
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
From Biodesix
Via Business Wire
Biodesix to Present at the William Blair 41st Annual Growth Stock Conference
From Biodesix, Inc.
Via Business Wire
Biodesix Announces First Quarter 2021 Results
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans
From Biodesix, Inc.
Via Business Wire
Biodesix to Report First Quarter 2021 Financial Results on May 11, 2021
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Presentation on Use of Biomarker-Based Risk Assessment to Inform Lung Nodule Management
From Biodesix, Inc.
Via Business Wire
Biodesix Releases New Data at AACR on Proteomic Profiling to Help Guide Physician Treatment Strategies for NSCLC Patients
From Biodesix, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.